Home LiteratureArticle Details
PMID: 17134371 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Immunosuppressive strategies that are mediated by tumor cells.

Annual review of immunology ·Vol. 25 ·2007-00-00 ·Pages 267-96

Rabinovich GA, Gabrilovich D, Sotomayor EM

Abstract

Despite major advances in understanding the mechanisms leading to tumor immunity, a number of obstacles hinder the successful translation of mechanistic insights into effective tumor immunotherapy. Such obstacles include the ability of tumors to foster a tolerant microenvironment and the activation of a plethora of immunosuppressive mechanisms, which may act in concert to counteract effective immune responses. Here we discuss different strategies employed by tumors to thwart immune responses, including tumor-induced impairment of antigen presentation, the activation of negative costimulatory signals, and the elaboration of immunosuppressive factors. In addition, we underscore the influence of regulatory cell populations that may contribute to this immunosuppressive network; these include regulatory T cells, natural killer T cells, and distinct subsets of immature and mature dendritic cells. The current wealth of preclinical information promises a future scenario in which the synchronized blockade of immunosuppressive mechanisms may be effective in combination with other conventional strategies to overcome immunological tolerance and promote tumor regression.

MeSH Terms
Animals Antigen Presentation/immunology Dendritic Cells/immunology,pathology Humans Immune Tolerance Immunosuppressive Agents/immunology Killer Cells, Natural/immunology,pathology Neoplasms/immunology,pathology,therapy T-Lymphocytes, Regulatory/immunology,pathology Tumor Escape/immunology
Chemicals
Immunosuppressive Agents
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Rabinovich Gabriel A
Division of Immunogenetics, Hospital de Clínicas José de San Martín, University of Buenos Aires, Buenos Aires, Argentina. [email protected]
Gabrilovich Dmitry
Sotomayor Eduardo M
References (186)
186 references, click to expand
  1. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
    Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4712-7 PMID: 12682289
  2. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.
    Nat Med. 2003 May;9(5):562-7 PMID: 12704383
  3. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo.
    Immunity. 2003 May;18(5):605-17 PMID: 12753738
  4. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas.
    J Pathol. 2003 Jun;200(2):255-68 PMID: 12754747
  5. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1.
    Nat Immunol. 2003 Jul;4(7):670-9 PMID: 12796776
  6. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
    Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7 PMID: 12826605
  7. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species.
    J Leukoc Biol. 2003 Aug;74(2):186-96 PMID: 12885935
  8. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion.
    J Immunol. 2003 Aug 15;171(4):1652-5 PMID: 12902462
  9. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.
    J Exp Med. 2003 Aug 18;198(4):569-80 PMID: 12925674
  10. Adoptive-cell-transfer therapy for the treatment of patients with cancer.
    Nat Rev Cancer. 2003 Sep;3(9):666-75 PMID: 12951585
  11. Cancer vaccines: between the idea and the reality.
    Nat Rev Immunol. 2003 Aug;3(8):630-41 PMID: 12974478
  12. A critical role for Stat3 signaling in immune tolerance.
    Immunity. 2003 Sep;19(3):425-36 PMID: 14499117
  13. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.
    Nat Med. 2003 Oct;9(10):1269-74 PMID: 14502282
  14. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer.
    Cancer Res. 2003 Oct 1;63(19):6478-87 PMID: 14559840
  15. Modulation of tryptophan catabolism by regulatory T cells.
    Nat Immunol. 2003 Dec;4(12):1206-12 PMID: 14578884
  16. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.
    J Exp Med. 2003 Dec 1;198(11):1741-52 PMID: 14657224
  17. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis.
    Cancer Res. 2003 Dec 1;63(23):8302-11 PMID: 14678989
  18. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer.
    J Immunol. 2004 Jan 1;172(1):464-74 PMID: 14688356
  19. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens.
    Cancer Res. 2003 Dec 15;63(24):9007-15 PMID: 14695219
  20. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells.
    Nat Med. 2004 Jan;10(1):48-54 PMID: 14702634
  21. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.
    J Immunol. 2004 Jan 15;172(2):989-99 PMID: 14707072
  22. Role of immature myeloid Gr-1+ cells in the development of antitumor immunity.
    Cancer Res. 2004 Feb 1;64(3):1130-9 PMID: 14871848
  23. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.
    Cancer Res. 2004 Feb 1;64(3):1140-5 PMID: 14871849
  24. Bystander elimination of antigen loss variants in established tumors.
    Nat Med. 2004 Mar;10(3):294-8 PMID: 14981514
  25. Is cancer dangerous to the immune system?
    Semin Immunol. 1996 Oct;8(5):271-80 PMID: 8956455
  26. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells.
    Am J Pathol. 1997 Feb;150(2):641-51 PMID: 9033277
  27. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement.
    Immunity. 1997 Apr;6(4):411-7 PMID: 9133420
  28. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats.
    Int J Cancer. 1997 Aug 7;72(4):619-24 PMID: 9259401
  29. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma.
    Int J Cancer. 1997 Nov 4;73(3):309-16 PMID: 9359474
  30. Induction of tolerance by IL-10-treated dendritic cells.
    J Immunol. 1997 Nov 15;159(10):4772-80 PMID: 9366401
  31. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2.
    Nat Med. 1998 Jan;4(1):43-9 PMID: 9427605
  32. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression.
    Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1178-83 PMID: 9448305
  33. Tolerance and cancer: a critical issue in tumor immunology.
    Crit Rev Oncog. 1996;7(5-6):433-56 PMID: 9467666
  34. Minimal recruitment and activation of dendritic cells within renal cell carcinoma.
    Clin Cancer Res. 1998 Mar;4(3):585-93 PMID: 9533525
  35. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity.
    J Immunol. 1998 Jan 15;160(2):643-51 PMID: 9551898
  36. Prevention of allogeneic fetal rejection by tryptophan catabolism.
    Science. 1998 Aug 21;281(5380):1191-3 PMID: 9712583
  37. Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors.
    J Immunol. 1998 Nov 1;161(9):4842-51 PMID: 9794417
  38. Decreased antigen presentation by dendritic cells in patients with breast cancer.
    Clin Cancer Res. 1997 Mar;3(3):483-90 PMID: 9815709
  39. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells.
    J Immunol. 1998 Nov 15;161(10):5313-20 PMID: 9820504
  40. Regulation of the proinflammatory effects of Fas ligand (CD95L).
    Science. 1998 Nov 27;282(5394):1714-7 PMID: 9831564
  41. Human melanoma cells do not express Fas (Apo-1/CD95) ligand.
    Cancer Res. 1999 Jan 1;59(1):59-62 PMID: 9892185
  42. Immune escape of tumors: apoptosis resistance and tumor counterattack.
    J Leukoc Biol. 2002 Jun;71(6):907-20 PMID: 12050175
  43. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck.
    Clin Cancer Res. 2002 Jun;8(6):1787-93 PMID: 12060618
  44. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?
    Trends Immunol. 2002 Jun;23(6):313-20 PMID: 12072371
  45. Immature myeloid cells and cancer-associated immune suppression.
    Cancer Immunol Immunother. 2002 Aug;51(6):293-8 PMID: 12111117
  46. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
    Nat Med. 2002 Aug;8(8):793-800 PMID: 12091876
  47. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase.
    Science. 2002 Sep 13;297(5588):1867-70 PMID: 12228717
  48. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
    Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7 PMID: 12218188
  49. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation.
    Nature. 2002 Oct 17;419(6908):734-8 PMID: 12384702
  50. The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens.
    J Exp Med. 2002 Oct 21;196(8):1099-104 PMID: 12391021
  51. Natural selection of tumor variants in the generation of "tumor escape" phenotypes.
    Nat Immunol. 2002 Nov;3(11):999-1005 PMID: 12407407
  52. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction.
    Immunol Rev. 2002 Oct;188:97-113 PMID: 12445284
  53. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
    J Exp Med. 2002 Dec 16;196(12):1627-38 PMID: 12486105
  54. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice.
    J Immunol. 2003 Jan 1;170(1):270-8 PMID: 12496409
  55. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells.
    Science. 2003 Feb 14;299(5609):1033-6 PMID: 12532024
  56. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity.
    Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1879-84 PMID: 12571365
  57. Tolerogenic dendritic cells.
    Annu Rev Immunol. 2003;21:685-711 PMID: 12615891
  58. Does the immune system see tumors as foreign or self?
    Annu Rev Immunol. 2003;21:807-39 PMID: 12615893
  59. Immune surveillance against a solid tumor fails because of immunological ignorance.
    Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2233-8 PMID: 10051624
  60. A new era for cancer immunotherapy based on the genes that encode cancer antigens.
    Immunity. 1999 Mar;10(3):281-7 PMID: 10204484
  61. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story.
    Mol Med Today. 1999 Apr;5(4):178-86 PMID: 10203751
  62. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.
    Nat Med. 1999 Jun;5(6):677-85 PMID: 10371507
  63. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.
    Nat Med. 1999 Jul;5(7):774-9 PMID: 10395322
  64. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40.
    Nat Med. 1999 Jul;5(7):780-7 PMID: 10395323
  65. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.
    Cancer Res. 1999 Jul 1;59(13):3128-33 PMID: 10397255
  66. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1.
    Nat Med. 1999 Aug;5(8):938-42 PMID: 10426319
  67. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    J Exp Med. 1999 Aug 2;190(3):355-66 PMID: 10430624
  68. Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis.
    J Exp Med. 1999 Aug 2;190(3):385-98 PMID: 10430627
  69. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
    Immunity. 1999 Aug;11(2):141-51 PMID: 10485649
  70. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance.
    Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11476-81 PMID: 10500201
  71. A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions.
    J Immunol. 1999 Nov 1;163(9):4886-93 PMID: 10528190
  72. IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage.
    J Clin Invest. 2004 Nov;114(10):1372-8 PMID: 15545984
  73. Plasmacytoid dendritic cells in immunity.
    Nat Immunol. 2004 Dec;5(12):1219-26 PMID: 15549123
  74. Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions.
    Am J Pathol. 2004 Dec;165(6):1853-63 PMID: 15579430
  75. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
    J Exp Med. 2000 Oct 2;192(7):1027-34 PMID: 11015443
  76. Galectin-1 induces partial TCR zeta-chain phosphorylation and antagonizes processive TCR signal transduction.
    J Immunol. 2000 Oct 1;165(7):3722-9 PMID: 11034377
  77. Reversal of CD8+ T cell ignorance and induction of anti-tumor immunity by peptide-pulsed APC.
    J Immunol. 2000 Dec 15;165(12):6731-7 PMID: 11120791
  78. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer.
    J Immunol. 2001 Jan 1;166(1):678-89 PMID: 11123353
  79. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation.
    Nature. 2001 Feb 8;409(6821):733-9 PMID: 11217864
  80. Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of high-affinity CD8+ T cells or CTL immunotherapy of tumors expressing the antigen.
    J Immunol. 2001 Feb 15;166(4):2863-70 PMID: 11160355
  81. Immune privilege or inflammation? Insights into the Fas ligand enigma.
    Nat Med. 2001 Mar;7(3):271-4 PMID: 11231613
  82. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity.
    Nat Immunol. 2000 Dec;1(6):469-74 PMID: 11101867
  83. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function.
    Clin Cancer Res. 1999 Oct;5(10):2963-70 PMID: 10537366
  84. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
    J Immunol. 1999 Nov 15;163(10):5211-8 PMID: 10553041
  85. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.
    Adv Immunol. 2000;74:181-273 PMID: 10605607
  86. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation.
    J Immunol. 2000 Mar 1;164(5):2405-11 PMID: 10679076
  87. Clinical significance of defective dendritic cell differentiation in cancer.
    Clin Cancer Res. 2000 May;6(5):1755-66 PMID: 10815894
  88. Immunology at the maternal-fetal interface: lessons for T cell tolerance and suppression.
    Annu Rev Immunol. 2000;18:367-91 PMID: 10837063
  89. Immunobiology of dendritic cells.
    Annu Rev Immunol. 2000;18:767-811 PMID: 10837075
  90. Expression of intestine-specific antigen reveals novel pathways of CD8 T cell tolerance induction.
    Immunity. 2000 May;12(5):505-14 PMID: 10843383
  91. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway.
    Nat Immunol. 2000 Dec;1(6):515-20 PMID: 11101874
  92. A fresh look at tumor immunosurveillance and immunotherapy.
    Nat Immunol. 2001 Apr;2(4):293-9 PMID: 11276199
  93. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells.
    J Immunol. 2001 May 1;166(9):5398-406 PMID: 11313376
  94. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.
    Nature. 2001 Apr 26;410(6832):1107-11 PMID: 11323675
  95. A potential immune escape mechanism by melanoma cells through the activation of chemokine-induced T cell death.
    Curr Biol. 2001 May 1;11(9):691-6 PMID: 11369232
  96. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.
    Cancer Res. 2001 Jun 15;61(12):4756-60 PMID: 11406548
  97. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance.
    Nat Med. 2001 Aug;7(8):907-12 PMID: 11479622
  98. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression.
    Blood. 2001 Aug 15;98(4):1070-7 PMID: 11493453
  99. Regulation of T cell immunity by dendritic cells.
    Cell. 2001 Aug 10;106(3):263-6 PMID: 11509174
  100. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.
    Nat Med. 2001 Oct;7(10):1118-22 PMID: 11590434
  101. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells.
    Nat Med. 2001 Dec;7(12):1339-46 PMID: 11726975
  102. The role of Fas ligand in immune privilege.
    Nat Rev Mol Cell Biol. 2001 Dec;2(12):917-24 PMID: 11733771
  103. Antigen presentation and T cell stimulation by dendritic cells.
    Annu Rev Immunol. 2002;20:621-67 PMID: 11861614
  104. Mouse and human dendritic cell subtypes.
    Nat Rev Immunol. 2002 Mar;2(3):151-61 PMID: 11913066
  105. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles.
    J Exp Med. 2002 May 20;195(10):1303-16 PMID: 12021310
  106. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance.
    Cancer Cell. 2005 Nov;8(5):369-80 PMID: 16286245
  107. A population of HLA-DR+ immature cells accumulates in the blood dendritic cell compartment of patients with different types of cancer.
    Neoplasia. 2005 Dec;7(12):1112-22 PMID: 16354594
  108. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity.
    Nat Immunol. 2005 Dec;6(12):1245-52 PMID: 16286920
  109. Breaking down the barriers to cancer immunotherapy.
    Nat Immunol. 2005 Dec;6(12):1207-10 PMID: 16369561
  110. SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling.
    J Clin Invest. 2006 Jan;116(1):90-100 PMID: 16357940
  111. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen.
    J Immunol. 2006 Jan 15;176(2):974-83 PMID: 16393983
  112. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines.
    Blood. 2006 Jan 15;107(2):628-36 PMID: 16179369
  113. Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3.
    Proc Natl Acad Sci U S A. 2006 Jan 3;103(1):153-8 PMID: 16371463
  114. Effective cancer therapy through immunomodulation.
    Annu Rev Med. 2006;57:65-81 PMID: 16409137
  115. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host.
    Cancer Res. 2006 Jan 15;66(2):1123-31 PMID: 16424049
  116. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention.
    Semin Cancer Biol. 2006 Feb;16(1):3-15 PMID: 16153857
  117. Restoring function in exhausted CD8 T cells during chronic viral infection.
    Nature. 2006 Feb 9;439(7077):682-7 PMID: 16382236
  118. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors.
    Nat Med. 2006 Mar;12(3):335-41 PMID: 16474399
  119. Transforming growth factor-beta regulation of immune responses.
    Annu Rev Immunol. 2006;24:99-146 PMID: 16551245
  120. Human T cell responses against melanoma.
    Annu Rev Immunol. 2006;24:175-208 PMID: 16551247
  121. In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity.
    Blood. 2006 Apr 1;107(7):2871-8 PMID: 16339406
  122. Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells.
    Cancer Res. 2006 Apr 1;66(7):3629-38 PMID: 16585188
  123. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.
    Cancer Cell. 2005 Mar;7(3):239-49 PMID: 15766662
  124. NK cell recognition.
    Annu Rev Immunol. 2005;23:225-74 PMID: 15771571
  125. Immunosuppressive networks in the tumour environment and their therapeutic relevance.
    Nat Rev Cancer. 2005 Apr;5(4):263-74 PMID: 15776005
  126. Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells.
    Eur J Immunol. 2005 Apr;35(4):1155-63 PMID: 15761844
  127. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion.
    J Immunol. 2005 Apr 15;174(8):4880-91 PMID: 15814715
  128. TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells.
    J Immunol. 2005 May 1;174(9):5215-23 PMID: 15843517
  129. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response.
    J Exp Med. 2005 May 16;201(10):1591-602 PMID: 15883172
  130. In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses.
    J Exp Med. 2005 May 16;201(10):1531-41 PMID: 15897272
  131. Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70.
    Cancer Res. 2005 Jun 15;65(12):5428-38 PMID: 15958592
  132. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function.
    Science. 2005 Aug 26;309(5739):1380-4 PMID: 16123302
  133. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.
    Nature. 2005 Sep 1;437(7055):141-6 PMID: 16136144
  134. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells.
    J Immunol. 2005 Oct 1;175(7):4583-92 PMID: 16177103
  135. Tumor counterattack: fact or fiction?
    Cancer Immunol Immunother. 2005 Nov;54(11):1127-36 PMID: 15889255
  136. NF-kappaB: linking inflammation and immunity to cancer development and progression.
    Nat Rev Immunol. 2005 Oct;5(10):749-59 PMID: 16175180
  137. IL-12 and IL-10 expression synergize to induce the immune-mediated eradication of established colon and mammary tumors and lung metastasis.
    J Immunol. 2005 Nov 1;175(9):5885-94 PMID: 16237081
  138. Interleukin-10 and the immune response against cancer: a counterpoint.
    J Leukoc Biol. 2005 Nov;78(5):1043-51 PMID: 16204623
  139. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
    Cancer Res. 2005 Nov 1;65(21):9817-23 PMID: 16267003
  140. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma.
    J Exp Med. 2006 Apr 17;203(4):871-81 PMID: 16606666
  141. Regulatory T cells in human disease and their potential for therapeutic manipulation.
    Immunology. 2006 May;118(1):1-9 PMID: 16630018
  142. Mechanisms of immune evasion by tumors.
    Adv Immunol. 2006;90:51-81 PMID: 16730261
  143. Checkpoint blockade in cancer immunotherapy.
    Adv Immunol. 2006;90:297-339 PMID: 16730267
  144. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity.
    Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9190-5 PMID: 16754847
  145. The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity?
    Nat Rev Immunol. 2006 Aug;6(8):613-8 PMID: 16868552
  146. Galectin-1: a small protein with major functions.
    Glycobiology. 2006 Nov;16(11):137R-157R PMID: 16840800
  147. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
    J Clin Invest. 2006 Jul;116(7):1935-45 PMID: 16778987
  148. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease.
    Cancer Res. 2004 Mar 15;64(6):2205-11 PMID: 15026364
  149. The three Es of cancer immunoediting.
    Annu Rev Immunol. 2004;22:329-60 PMID: 15032581
  150. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.
    Annu Rev Immunol. 2004;22:531-62 PMID: 15032588
  151. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege.
    Cancer Cell. 2004 Mar;5(3):241-51 PMID: 15050916
  152. A spontaneously arising pancreatic tumor does not promote the differentiation of naive CD8+ T lymphocytes into effector CTL.
    J Immunol. 2004 Jun 1;172(11):6558-67 PMID: 15153470
  153. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.
    J Clin Invest. 2004 Jul;114(2):280-90 PMID: 15254595
  154. A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and Transporter associated with Antigen Processing 1/2 in human melanoma cells.
    J Immunol. 2004 Aug 1;173(3):1731-7 PMID: 15265902
  155. Role of TGF-beta in cancer and the potential for therapy and prevention.
    Expert Rev Anticancer Ther. 2004 Aug;4(4):649-61 PMID: 15270668
  156. Galectins as modulators of tumour progression.
    Nat Rev Cancer. 2005 Jan;5(1):29-41 PMID: 15630413
  157. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance.
    Blood. 2005 Feb 1;105(3):1135-43 PMID: 15454486
  158. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
    Cancer Immunol Immunother. 2005 Apr;54(4):307-14 PMID: 15599732
  159. Defective proximal TCR signaling inhibits CD8+ tumor-infiltrating lymphocyte lytic function.
    J Immunol. 2005 Feb 15;174(4):1830-40 PMID: 15699109
  160. Tumour-derived exosomes or microvesicles: another mechanism of tumour escape from the host immune system?
    Br J Cancer. 2005 Jan 31;92(2):209-11 PMID: 15702078
  161. Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission.
    J Biol Chem. 2005 Feb 25;280(8):6969-85 PMID: 15556941
  162. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.
    Nat Med. 2005 Mar;11(3):312-9 PMID: 15711557
  163. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors.
    Cancer Res. 2005 Mar 1;65(5):2026-34 PMID: 15753403
  164. A simple method to cure established tumors by inflammatory killing of normal cells.
    Nat Biotechnol. 2004 Sep;22(9):1125-32 PMID: 15300260
  165. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
    Nat Med. 2004 Sep;10(9):942-9 PMID: 15322536
  166. Cancer immunotherapy: breaking the barriers to harvest the crop.
    Nat Med. 2004 Sep;10(9):887-92 PMID: 15340404
  167. Plasmacytoid dendritic cells activate lymphoid-specific genetic programs irrespective of their cellular origin.
    Immunity. 2004 Jul;21(1):43-53 PMID: 15345219
  168. Human galectin-2: novel inducer of T cell apoptosis with distinct profile of caspase activation.
    J Immunol. 2004 Sep 15;173(6):3825-37 PMID: 15356130
  169. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase.
    Int Immunol. 2004 Oct;16(10):1391-401 PMID: 15351783
  170. Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression.
    Cancer Cell. 2004 Sep;6(3):297-305 PMID: 15380520
  171. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.
    J Exp Med. 2004 Sep 20;200(6):771-82 PMID: 15381730
  172. Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma.
    J Immunol. 2004 Oct 1;173(7):4352-9 PMID: 15383564
  173. Manipulating dendritic cell biology for the active immunotherapy of cancer.
    Blood. 2004 Oct 15;104(8):2235-46 PMID: 15231572
  174. Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells.
    Nat Immunol. 2004 Nov;5(11):1124-33 PMID: 15475957
  175. Selective changes in expression of HLA class I polymorphic determinants in human solid tumors.
    Proc Natl Acad Sci U S A. 1989 Sep;86(17):6719-23 PMID: 2672003
  176. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance.
    Proc Natl Acad Sci U S A. 1990 Feb;87(4):1486-90 PMID: 2137615
  177. Split anergy in a CD8+ T cell: receptor-dependent cytolysis in the absence of interleukin-2 production.
    Science. 1991 Mar 8;251(4998):1228-31 PMID: 1900952
  178. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
    EMBO J. 1992 Nov;11(11):3887-95 PMID: 1396582
  179. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice.
    Science. 1992 Dec 11;258(5089):1795-8 PMID: 1465616
  180. Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA.
    J Clin Invest. 1993 Feb;91(2):684-92 PMID: 8432869
  181. Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors.
    Proc Natl Acad Sci U S A. 1994 May 24;91(11):4751-5 PMID: 8197130
  182. Apoptosis of T cells mediated by galectin-1.
    Nature. 1995 Dec 14;378(6558):736-9 PMID: 7501023
  183. Enhancement of antitumor immunity by CTLA-4 blockade.
    Science. 1996 Mar 22;271(5256):1734-6 PMID: 8596936
  184. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.
    Nat Med. 1996 Oct;2(10):1096-103 PMID: 8837607
  185. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
    Science. 1996 Nov 22;274(5291):1363-6 PMID: 8910274
  186. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma.
    Eur J Immunol. 1996 Nov;26(11):2671-9 PMID: 8921954
Article Info
Journal
Annual review of immunology
Abbr.
Annu Rev Immunol
ISSN
0732-0582
DOI
10.1146/annurev.immunol.25.022106.141609
Email
[email protected]
Published
2007-00-00
Pages
267-96
Language
English
Region
United States
NLM ID
8309206
PMCID
PMC2895922
Subset
IM
Grants
NCI NIH HHS · R01 CA084488 · United States
NCI NIH HHS · R01 CA084488-11 · United States
NCI NIH HHS · R01 CA100062 · United States
NCI NIH HHS · R01 CA100062-05 · United States
External Links
PubMed source DOI: 10.1146/annurev.immunol.25.022106.141609 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2